Clinical Trial Update: Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC [Phase 3]

View source ↗

Summary

Phase 3 LUME-Lung 2 trial comparing nintedanib (BIBF-1120) plus pemetrexed versus placebo plus pemetrexed in second-line non-squamous non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Nintedanib (nintedanib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2014-11-20